Arrowhead Pharmaceuticals Inc (ARWR) 銘柄情報

Quadruple Witching Day confirmed my thoughts on this. Looking at a 1 year chart we see in April 2024
it hit 22 then bounced to 25
Then back down and broke below 22 close to 21 but then went back up above 25
Then back down and tested that 22 and back up and took a few attempts but broke 26
Then back down below 23 but didn't touch 22 so higher lows and went up to break 25 but couldn't make a new high so back down it went to 23 but higher than the low before. So up it went to almost 27 a higher high...
Then back down to 23 and up to 28 then back down but didn't get below 24 so a higher low and up it went to 29 and then broke 30
THEN...
Down down down and looks like a new pattern forming...
Down to 17 and up above 21
Down to 19 up to 22.50 but then a crash down to 18 which is still higher low than 17...and starts to come up and hit about 20...But the unexpected happens. SRPT
POP up to 24 early and slowly slides back down but next day earnings and up it goes again breaking 26 and hanging around 27 a few days...Then beat down to 22 and bounces to 24 a few days then beat down to 22 a few days and then BEAT DOWN to low 19 today and also run to 20 and has an interesting look to todays candle. It opened a hair lower than where it closed today looking like a Doji candle.
Now charts just show where we've been, not always where we are going but...This chart sure looks promising but you never know...

Looking at the chart I think we hit 25/26 area in Jan then pull back to 20/20.50 and head up again. We will have to wait and see.

Gap filled
Added what I sold back...Wwweeee
Triple Witching Friday ohhh scary.

remember they are basically out of the AMGN deal

Maybe this comes to life here... Super action - now partnered with AMGN and SRPT....

"$AMGN CEO said last week that Lpa-#RNAi from $ARWR (olpasiran) is his favorite compound.

Add to this new CSO a hard-core RNA scientist from Stanford, you can see where this movie is going..."
https://x.com/RNAiAnalyst/status/1865531213726765299

Sold the shares for a small profit but still holding calls. Wanted to deploy the funds to another play that filled the gap and I'll add those shares back here if ARWR does the same gap fill.

I got 10 each with March (20) ITM first, then OTM (30) as it kept falling and finished with 1000 shares. Planning on adding more if it turns those ITM calls to OTM before the new year. lol
I wanted them after the next earnings but might try the January ones if we get a big fast dip.

I'm curious as to which calls you like. Near term, long term, in the money, out of the money? I haven't bought any yet, but I'm kind of liking the deep in the money Jun '25 calls as a way to get a little leverage for not much cost, and then maybe a little at the money or out of the money for more speculative dollars. What's your approach?

Added shares and calls on pull back. 2025 lets roll...

Looking good but I took profits. Had 10 (23) calls under 2 just sold 4.50 so 2500 to go gobble gobble. ARWR's future looks really good but I'm trading at the moment. Got other plays I'm more focused on and I probably would have exercised those calls and I'd rather take some small profits and have that dry powder to deploy again. BooYAHHH
Don't worry I always leave too early as I did the same thing making twice as much on SMCI. Just enjoy the rides no need to put a ring on it

Booyahhh. Got in yesterday on the pull back as I saw it fell once it hit the 200DMA . It's right there again but I'm just going to hold because the deal is a lot of cash that's needed and bring certainty to ARWR's future. So I'll buy deep dips and sell flippers on rips while keeping a core.

super deal for both parties
SRPT AAV-based seeking RNAI for additional opportunitites........
https://finance.yahoo.com/news/arrowhead-pharmaceuticals-announces-global-license-120000908.html

$29.18- $39.45 profit zone

ARWR $24 + 27% Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years.Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales.Sarepta to receive investigational treatments that leverage Arrowhead's leading Targeted RNAi Molecule platform.Arrowhead to discuss this agreement during the company's 2024 fiscal year end results conference call today, November 26, 2024, at 4:30 p.m. ET.

Should be a good Tuesday
https://finance.yahoo.com/news/arrowhead-pharmaceuticals-presents-pivotal-phase-103600472.html

ARWR over $20

CEO speaks
https://www.biotechtv.com/post/arrowhead-pharmaceuticals-february-1-2024

I'm new to all of this and perhaps it shows, but if I understand this correctly, CNTX reports enough $$ (only) to carry them through the end of '24. Seems a pretty large caveat...

ARWR was beaten down once and here is another one

Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)

(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.


Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened. 

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share.  ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to  Viking Therapeutics it had the same beat down before running up to over $25 a share.  In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023.  Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.

Due your own research and the wise will should agree.

ARWR still ascending.
Entered yesterday.
I added 40% more this morning on the strength of the chart
Average is 36.17
1/19 Data Report date
Limited DD
https://stockcharts.com/h-sc/ui?s=ARWR

Arrowhead is an amazing company. Gene silencing is a world away from gene editing.

NEWS: $ARWR Why Arrowhead Pharmaceuticals Stock Jumped Today

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) rose sharply on Thursday and closed today's trading session up 9.9% after climbing by as much as 14.4%. The drugmaker did not report any news, but biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX) released an update regardin...

In case you are interested ARWR - Why Arrowhead Pharmaceuticals Stock Jumped Today

* * $ARWR Video Chart 09-16-2020 * *

Link to Video - click here to watch the technical chart video

ARWR $weet upside run....check out QRTEB > nice upside as well.

Lucky folks that own IPO shares of SNOW > $$$$$

great gapper this one today

Arrowhead Pharmaceuticals shares are trading higher after the company announced positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company's second-generation investigational RNA interference therapeutic.

ARWR

ARWR MOVING VERY SWIFTLY TOO FOR A STOCK WITH 102M SHARES

Breaking News: $ARWR Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment

- Up to 97% reduction in intra-hepatic Z-AAT polymer - Up to 95% reduction in intra-hepatic total Z-AAT burden - Up to 66% and 58% reduction in circulating ALT and GGT levels respectively - Up to 26% improvement in FibroScan values Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)...

Find out more ARWR - Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment

guess you got your wish

Lurking for entry sub $40...eom

Happy options expirations day!

http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-doses-first-patient-aroaat2002-open

No changes in the company besides positive. Has to be manipulation, imo. All good after options expire Friday.

So its down sharply on good news?

http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-regulatory-clearance-begin-4

That is sad.
Companies that used them should take responsibility for their care. The gov. should compel them to.

BTW. The drugs used must have been good. According to the article they were dumped there since the 70s. ARWR wasn't around then, I think.

I'm no ARWR millionaire yet, but yes, these chimps need some fruits, nuts etc. I know a lot of them at yahoo board. Uhh… some millionaires too.

Looks like there will be a lot more of them shortly. ARWR may head higher. She will be flying high in the SP 400 midcap soon. So come on brudahs! Kokua! Malama!

I am keeping the link just in case... Aloha!

$ARWR upgraded to S&P MidCap 400 index starting 12/23

https://twitter.com/sonichedgefund/status/1205616137582460928?s=19

Liberia’s Monkey Island, Charity
As there are now a few “ARWR millionaires” on this board please consider making a donation to The Humane Society to benefit Liberia’s Monkey Island. These chimps are for lab testing subjects that have been abandoned on an island with little to no food they can gather for themselves. They rely on people bringing them food. A portion of the chimp population was used for Hepatitis B testing. Some of the “ARWR millionaires” bought shares at absurdly low prices in part due to ARWR proving that ARC-520 could knock down HBsAg in HBV infected chimps. Read more details below and keep the link incase you need to send it to a Humane Society rep to describe where you want your money to go to:

https://m.greenwichtime.com/news/article/U-S-lab-chimps-were-dumped-on-Liberia-s-Monkey-14901091.php

I can’t post this to Y!Finance and I don’t have Twitter at the moment so if you want to spread this around, be my guest. The Chimps need to collect their dividend!

link to donate
https://www.liberiachimps.org/donate?utm_source=syndication&s_src=mr_mr_liberiadonate12122019&credit=mr&utm_campaign=liberia_chimps&utm_medium=mr

$ARWR bears are running Arrowhead Pharmaceuticals Inc Nasdaq Arwr Short Squeeze

Nice pennant formation.

Targets?
Base $52 73-52=21 21+73=$94!
Base $42 73-42=31 31+73=$104!?

need to break 73

News: $ARWR Here's Why Arrowhead Pharmaceuticals Is Soaring Today

Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) gained as much as 14.4% today after the company announced a public stock offering. It seems counterintuitive, but investors appear to be excited about a snippet of text listing possible uses for the proceeds. The company made the standard e...

In case you are interested ARWR - Here's Why Arrowhead Pharmaceuticals Is Soaring Today

News: $ARWR Don't Waste Your Money on Penny Stocks; These 3 Companies Are Better Buys

There's a certain excitement to buying penny stocks and being able to control a large number of shares with comparatively little cash outlay. Even small movements in the share price can generate substantial returns. But penny stocks rarely give investors such opportunities, and most turn into b...

Got this from ARWR - Don't Waste Your Money on Penny Stocks; These 3 Companies Are Better Buys

Looks like a lot of people got whipsawed.
Now they are looking to get back their positions.

Hanging tight on this stock seems to be a good strategy.
The science is cutting edge. A buyout is in the calendar but then a secondary changes that. imo.

A secondary was also a way for the shorts to escape.

It’s down 5% more in after hours from a secondary announcement

Wow... that's a haircut.

Arwr is doing close to 45 million in revenue each quarter.
I do think a PE of 105 is far ahead of itself

I think qbio is going to do that within a year .(2021)
You do the math.only 16.7 million shares there ,ARWR 95 millon shares

Commercialization of product 2020
product going into phase 2-3 2020
possible uplisting nasdaq 2020

I think it can for sure.

They got great products ,one commercialization in 2020 .
That is a potential 500 million in revenue within 2-3 years
Because it's a proven product and know by doctors that are facing patients with bonecancer . could be used for other painrelief then that.

Also there autistic orphandrug is about to go in phase 2-3
If so even in the trials it's worth a lot of money.
potential 2 billion in revenue.

Also the mannin divison in europe has got a grant from the government .
governments are conservative ,when you throw 7.5 million $ at it you almost know this is going to make it.

There was recent interest in mannin by big pharma accoring to the ceo.

Qbio could indeed be the next ARWR.

Also a big positive is the amazing share structure

Can QBIO end up as high as this stock one day?

it's likely headed to a market cap of $9.7 Billion. The buyout price of MDCO. I think it's doable. ARWR has better pipeline than them.

I need to send someone a fruit basket... Should have bought more.....

Another increased PT. $81.00/share

https://www.analystratings.com/articles/arrowhead-research-arwr-receives-a-buy-from-chardan-capital/?ref=tipranks